Vivet presenting at ARM 2019 Cell & Gene Meeting on the Med in Barcelona
Jean-Philippe Combal, Vivet CEO, will be attending a panel
Vivet Therapeutics Announces 2 Abstracts Accepted For Oral Presentation At 2019 ASGCT
Paris, France, April 24, 2019 – Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments
VIVET PRESENTING LEAD PRODUCT, VTX-801, AND PFIC INDICATION VTX-803, AT 2019 INTERNATIONAL LIVER CONGRESS
Vivet Therapeutics will be making a presentation on its lead product
VIVET ATTENDING 3RD ANNUAL GENE THERAPY FOR RARE DISORDERS CONFERENCE IN BOSTON
Jean-Philippe Combal, Vivet Therapeutics’ CEO, will be attending the 3rd Annual Gene Therapy for Rare Disorders conference in Boston (March 26-28 2019).
Vivet presenting during the 2019 Bioprocessing Summit Europe in Lisbon
Vivet Therapeutics’ CEO, Jean-Philippe Combal
Vivet attending DIA Europe 2019 in Vienna on February 5-7
Anne Douar, Chief Development Officer of Vivet Therapeutics
VIVET WILL BE AT THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Jean-Philippe Combal, Vivet Therapeutics’ CEO
Vivet presenting at 2018 Evercore ISI HEALTHCONx in Boston
Vivet Therapeutics CEO, Jean-Philippe Combal
VIVET ATTENDING JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE
Jean-Philippe Combal, Vivet Therapeutics’ CEO, and Thomas Daniel, BD Director, will be hosting 1×1 meetings during Jefferies 2018 London Healthcare Conference on…
VIVET PRESENTING DURING 2018 GENE THERAPY FOR RARE DISORDERS EUROPE CONFERENCE IN LONDON
Anne Douar, Chief Development Officer of Vivet Therapeutics
